The advent of artificial intelligence (AI) tools and agents have revolutionised medicine and healthcare. Patients and caregivers of Alzheimer’s disease (AD), as well as numerous other aging-related neurodegenerative diseases, could benefit from various AI-enabled technological advancements pertaining to disease modelling, drug discovery, data processing and patient support. With regards to the latter, generative AI-based chatbots have been touted, and indeed adapted and marketed as AD apps, to provide disease progression monitoring, cognitive training, companionship and conversational support to lighten the burden of human caregivers [1]. Such AI apps are generally perceived to be non-invasive and thus carry fewer risks for patients. However, generative AI chatbots are nonetheless cognitively invasive, and as such do carry unseen risks that need to be addressed.